Akoya Biosciences (NASDAQ:AKYA) announced that it has entered into an exclusive global licencing agreement with NeraCare to develop and commercialize NeraCare’s Immunoprint test for guiding early-stage melanoma treatment decisions on Akoya’s multiplex immunofluorescent platform.
The agreement grants Akoya the exclusive right to develop, market, and commercialize the test for clinical research, diagnostic development, or, upon regulatory approval, clinical testing as both a laboratory-based test and a distributable diagnostic on Akoya’s Phenolmager HT Platform.
“The agreement builds on the complementary expertise of both companies: Akoya’s market-leading multiplex immunofluorescence technology and NeraCare’s innovative development and rigorous clinical validation of Immunoprint,” said Friedrich Ackermann, co-founder of NeraCare. “Together, we aim to expand access to life-saving therapies for early-stage melanoma patients worldwide.”
“Our collaboration is a testament to the versatility of Akoya’s PhenoImager HT platform and the clinical impact spatial biology can deliver. Immunoprint has proven unparalleled in identifying high-risk melanoma patients through multiple clinical studies, and our partnership aims to offer a platform to address the unmet need for earlier therapeutic intervention,” added Daniel von Janowski, co-founder of NeraCare.
Brian McKelligon, CEO of Akoya, stated, “Our exclusive partnership with NeraCare for Immunoprint is a significant advancement of our clinical strategy providing Akoya and our pharmaceutical partners the opportunity to transform melanoma patient care. We are honored to be partnering with NeraCare to help bring this test to market and serve a critical unmet need.”
